The earnings call showcased strong year-over-year revenue growth and improved gross margins, indicating a positive trajectory for Champions Oncology. Strategic investments in radiolabeling and the data platform are expected to drive long-term growth. However, increased operating expenses and cash flow challenges present areas of concern. Overall, the company's positive financial performance and strategic direction suggest a favorable outlook.

Company Guidance

During the Champions Oncology second quarter fiscal 2026 earnings call, CEO Robert Brainin outlined key guidance metrics for the company. Champions Oncology aims to achieve year-on-year revenue growth and maintain positive adjusted EBITDA for the full year. The company posted a total revenue of $15 million for the quarter, up 11% from the previous year, with a gross margin improvement to 52% from 45%. Operating expenses rose to $7 million, reflecting strategic investments in the data platform and commercial team. Net cash used in operating activities was $1.9 million, with $8.5 million in cash and no debt. The company is focused on leveraging its unique radiolabeling capabilities and expanding its data platform to drive long-term growth, while maintaining fiscal discipline without shareholder dilution. The management remains optimistic about its performance in the upcoming quarters, given the improving market conditions and increasing customer engagement.

Year-over-Year Revenue Growth

Revenue for the second quarter was $15 million, an increase of 11% from $13.5 million last year, driven by improved conversion of booked work.

Improved Gross Margin

Gross margin improved to 52% from 45% last year, supported by operational efficiencies and a stable cost of sales.

Radiolabeling and Radiopharmaceutical Success

Continued success in radiolabeling and radiopharmaceutical support workflows, positioning Champions uniquely in the oncology drug development market.

Investment in Data Platform

Ongoing investment in enhancing the data platform's functionality to support pharmaceutical partners, with significant customer interest.

Positive Adjusted EBITDA

The company remains on track to achieve full-year positive adjusted EBITDA, one of its core financial goals for fiscal 2026.

Champions Oncology (CSBR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSBR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 17, 2026	2026 (Q3)	0.09 / -	0.36	―	―	―
Dec 15, 2025	2026 (Q2)	0.00 / 0.06	0.05	20.00% (<+0.01)	―
Sep 15, 2025	2026 (Q1)	-0.01 / 0.02	0.11	-81.82% (-0.09)	―
Jul 23, 2025	2025 (Q4)	-0.20 / -0.07	0.01	-800.00% (-0.08)	―
Mar 11, 2025	2025 (Q3)	-0.01 / 0.36	-0.16	325.00% (+0.52)	―
Dec 11, 2024	2025 (Q2)	0.01 / 0.05	-0.15	133.33% (+0.20)	―
Sep 11, 2024	2025 (Q1)	-0.03 / 0.11	-0.16	168.75% (+0.27)	―
Jul 18, 2024	2024 (Q4)	-0.16 / 0.01	-0.17	105.88% (+0.18)	―
Mar 12, 2024	2024 (Q3)	-0.06 / -0.16	-0.16	0.00% (0.00)	―
Dec 12, 2023	2024 (Q2)	-0.16 / -0.15	0.01	-1600.00% (-0.16)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSBR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Dec 15, 2025	$7.80	$6.73	-13.72%
Sep 15, 2025	$6.83	$8.30	+21.52%
Jul 23, 2025	$7.75	$6.65	-14.19%
Mar 11, 2025	$8.90	$9.79	+10.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Champions Oncology (CSBR) report earnings?

Champions Oncology (CSBR) is schdueled to report earning on Mar 17, 2026, After Close (Confirmed).

What is Champions Oncology (CSBR) earnings time?

Champions Oncology (CSBR) earnings time is at Mar 17, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSBR EPS forecast?

CSBR EPS forecast for the fiscal quarter 2026 (Q3) is 0.09.